Everolimus Teva 5 mg Tablets 아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

everolimus teva 5 mg tablets

teva b.v. - everolimus - tablet - 5 milligram(s) - protein kinase inhibitors; imatinib

Everolimus Teva 10 mg Tablets 아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

everolimus teva 10 mg tablets

teva b.v. - everolimus - tablet - 10 milligram(s) - protein kinase inhibitors; imatinib

Everolimus 2.5mg tablets 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

everolimus 2.5mg tablets

a a h pharmaceuticals ltd - everolimus - oral tablet - 2.5mg

Everolimus 5mg tablets 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

everolimus 5mg tablets

a a h pharmaceuticals ltd - everolimus - oral tablet - 5mg

Everolimus 10mg tablets 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

everolimus 10mg tablets

a a h pharmaceuticals ltd - everolimus - oral tablet - 10mg

Everolimus 2.5mg tablets 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

everolimus 2.5mg tablets

accord-uk ltd - everolimus - oral tablet - 2.5mg

Everolimus 5mg tablets 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

everolimus 5mg tablets

accord-uk ltd - everolimus - oral tablet - 5mg

Everolimus 10mg tablets 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

everolimus 10mg tablets

accord-uk ltd - everolimus - oral tablet - 10mg

EVEROCAN everolimus 1 mg tablet bottle pack 오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

everocan everolimus 1 mg tablet bottle pack

pharmacor pty ltd - everolimus, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose; hypromellose; acetone; lactose monohydrate; ethanol absolute; magnesium stearate; crospovidone; butylated hydroxytoluene - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

EVEROCAN everolimus 0.25 mg tablet blister pack 오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

everocan everolimus 0.25 mg tablet blister pack

pharmacor pty ltd - everolimus, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: ethanol absolute; lactose monohydrate; butylated hydroxytoluene; magnesium stearate; lactose; acetone; hypromellose; crospovidone - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).